Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI 62.5/25 mcg vs placebo in COPD (12-week, double-blind, randomized study)
2014-000529-19Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing UMEC/VI 62.5/25 mcg with Placebo (2 arms). Primary endpoint: St George's Respiratory Questionnaire (SGRQ) total score. Started Apr 2014; status: completed.
02
Drugs
Anoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-000529-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000529-19.